<\/p>\n\n
EU: CE marked for treatment of Major Depressive Disorder<\/h2>\n\n
MagVenture TMS Therapy\u00ae is CE marked for \u201cTreatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from two prior antidepressant medications, at or above the minimal effective dose and duration in the current episode\u201d. MagVenture TMS Therapy\u00ae is CE marked for \u201cTreatment of psychoactive substance use disorder (PSUD) in adult patients\u201d.<\/p>\n\n MagVenture TMS Therapy\u00ae is CE marked \u201cas an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).<\/p>\n\n The MagPro\u00ae is intended as an electro-physiological aid to assess diagnosis and to monitor diseases of the central and peripheral nervous system, based on the use of Motor Evoked Potential (MEP).<\/p><\/div><\/div><\/section> <\/p>","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-24506","page","type-page","status-publish","hentry"],"acf":{"hide_navigation":false,"navigation_color":"white-text","theme_color":"theme-color-dark-blue","hide_footer_instagram":false},"yoast_head":"\n
Clinical benefit:<\/strong> For subjects responding to the treatment of Major Depressive Disorder, who have symptoms of comorbid anxiety, the clinical benefit can additionally include an improvement of anxiety symptoms.<\/p>\n\nEU: CE marked for Addiction<\/h2>\n\n
EU: CE marked for adjunct treatment of OCD<\/h2>\n\n
EU: CE marked for diagnostic use<\/h2>\n\n